| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170520-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
| Ab170520-1mg | 1mg | In stock | $267.90 | |
| Ab170520-5mg | 5mg | In stock | $687.90 | |
| Ab170520-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,107.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Eptinezumab (anti-CGRP), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CALCA, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Calcitonin/calcitonin related polypeptide alpha antibody | Alpha type CGRP antibody | Beta type CGRP antibody | CALC1 antibody | CALC2 antibody | CALCA antibody | CALCB antibody | Calcitonin 1 antibody | Calcitonin 2 antibody | Calcitonin gene related pep |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | CALCA |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Calcitonin gene-related peptide inhibitor |
| Product Description | Eptinezumab is a human monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. Eptinezumab can be used for the prevention of migraine in adults. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 27.2 kDa (Light Chain) & 51.4 kDa (Heavy Chain), under reducing conditions; 179.3 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1644539-04-7 |
Eptinezumab (anti-CGRP) (Ab170520) - Flow Cytometry
Flow Cytometry analysis of A549 cells labelling CGRP (red) with Eptinezumab (anti-CGRP) (Ab170520). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Eptinezumab (anti-CGRP) (Ab170520) - SEC
The purity of Eptinezumab (anti-CGRP) (Ab170520) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 648 |
|---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1201921 | Certificate of Analysis | Dec 06, 2023 | Ab170520 |
| ZJ23F1201922 | Certificate of Analysis | Dec 06, 2023 | Ab170520 |
| 1. Mitsikostas DD, Reuter U. (2017) Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies.. Curr Opin Neurol, 30 (3): (272-280). [PMID:28240610] [10.1021/op500134e] |
| 2. Raffaelli B, Reuter U. (2018) The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.. Neurotherapeutics, 15 (2): (324-335). [PMID:29616494] [10.1021/op500134e] |
| 3. Edvinsson L. (2019) Role of CGRP in Migraine.. Handb Exp Pharmacol, 255 (13): (121-130). [PMID:30725283] [10.1021/op500134e] |
| 4. Scuteri D, Corasaniti MT, Tonin P, Bagetta G. (2019) Eptinezumab for the treatment of migraine.. Drugs Today, 55 (11): (695-703). [PMID:31840684] [10.1021/op500134e] |
| 5. Edvinsson L. (2018) The CGRP Pathway in Migraine as a Viable Target for Therapies.. Headache, 58 Suppl 1 (13): (33-47). [PMID:29697153] [10.1021/op500134e] |
| 6. Recober A, Russo AF. (2007) Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment.. IDrugs, 10 (8): (566-74). [PMID:17665333] [10.1021/op500134e] |
| 7. Migliore M, Habrant D, Sasso O, Albani C, Bertozzi SM, Armirotti A, Piomelli D, Scarpelli R. (2016) Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.. Eur J Med Chem, 109 (13): (216-37). [PMID:26774927] [10.1021/op500134e] |
| 8. Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, Wehn PM, Yang H, Dixon DD et al.. (2019) 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.. J Med Chem, 62 (15): (6876-6893). [PMID:31282155] [10.1021/op500134e] |
| 9. Miranda LP, Holder JR, Shi L, Bennett B, Aral J, Gegg CV, Wright M, Walker K, Doellgast G, Rogers R, Li H, Valladares V, Salyers K, Johnson E, Wild K.. (2008) Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor.. J Med Chem, 51 (24): (7889-7897). [PMID:19053766] [10.1021/jm8009298] |
| 10. Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.. (2016) Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines.. Bioorg Med Chem Lett, 26 (4): (1229-1232). [PMID:26832218] [10.1016/j.bmcl.2016.01.026] |
| 11. Waszkielewicz AM, Gunia-Krzyżak A, Powroźnik B, Słoczyńska K, Pękala E, Walczak M, Bednarski M, Żesławska E, Nitek W, Marona H.. (2016) Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.. Bioorg Med Chem, 24 (8): (1793-1810). [PMID:26988801] [10.1016/j.bmc.2016.03.006] |
| 12. Kitamura, K K and 5 more authors.. (1992) Isolation and characterization of peptides which act on rat platelets, from a pheochromocytoma.. Biochemical and biophysical research communications, (29): [PMID:1318039] |
| 13. Breeze, A L AL, Harvey, T S TS, Bazzo, R R and Campbell, I D ID.. (1991) Solution structure of human calcitonin gene-related peptide by 1H NMR and distance geometry with restrained molecular dynamics.. Biochemistry, (15): [PMID:1988044] |
| 14. Hubbard, J A JA and 5 more authors.. (1991) Solution structures of calcitonin-gene-related-peptide analogues of calcitonin-gene-related peptide and amylin.. The Biochemical journal, (1): [PMID:2039456] |
| 15. Edbrooke, M R MR and 6 more authors.. (1985) Expression of the human calcitonin/CGRP gene in lung and thyroid carcinoma.. The EMBO journal, [PMID:2408883] |
| 16. Broad, P M PM, Symes, A J AJ, Thakker, R V RV and Craig, R K RK.. (1989) Structure and methylation of the human calcitonin/alpha-CGRP gene.. Nucleic acids research, (12): [PMID:2571128] |
| 17. Craig, R K RK and 7 more authors.. (1986) Expression and function of the human calcitonin/alpha-CGRP gene in health and disease.. Biochemical Society symposium, [PMID:3034287] |
| 18. Petermann, J B JB, Born, W W, Chang, J Y JY and Fischer, J A JA.. (1987) Identification in the human central nervous system, pituitary, and thyroid of a novel calcitonin gene-related peptide, and partial amino acid sequence in the spinal cord.. The Journal of biological chemistry, (15): [PMID:3492492] |
| 19. Jonas, V V and 7 more authors.. (1985) Alternative RNA processing events in human calcitonin/calcitonin gene-related peptide gene expression.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:3872459] |
| 20. Nelkin, B D BD and 5 more authors.. (1984) Structure and expression of a gene encoding human calcitonin and calcitonin gene related peptide.. Biochemical and biophysical research communications, (17): [PMID:6148938] |
| 21. Morris, H R HR and 5 more authors.. (1984) Isolation and characterization of human calcitonin gene-related peptide.. Nature, [PMID:6609312] |
| 22. Steenbergh, P H PH and 5 more authors.. (1984) Calcitonin gene related peptide coding sequence is conserved in the human genome and is expressed in medullary thyroid carcinoma.. The Journal of clinical endocrinology and metabolism, [PMID:6610687] |
| 23. Dodick, David W DW and 13 more authors.. (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.. The Lancet. Neurology, [PMID:25297013] |
| 24. Monteith, David D and 8 more authors.. (2017) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.. Frontiers in pharmacology, [PMID:29089894] |
